202982-70-5

Basic information

• Product Name: 3-CHLORO-5-FLUOROPHENOL
• Synonyms: 3-CHLORO-5-FLUOROPHENOL;Phenol, 3-chloro-5-fluoro- (9CI);3-Chloro-5-fluorophenol 98%;3-Chloro-5-fluorophenol98%
• CAS NO: 202982-70-5
• Molecular Formula: C₆H₄ClFO
• Molecular Weight: 146.55
• Product Categories: ALCOHOL;HALIDE;Aromatic Phenols;Phenol&Thiophenol&Mercaptan;Chlorine Compounds;Fluorine Compounds;Phenols
• Mol File: 202982-70-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 205.977 °C at 760 mmHg
• Flash Point: 78.372 °C
• Appearance: /
• Density: 1.409 g/cm³
• Vapor Pressure: 0.17mmHg at 25°C
• Refractive Index: 1.537
• Storage Temp.: Room temperature.
• PKA: 8.01±0.10(Predicted)
• Water Solubility: Immiscible with water.
• CAS DataBase Reference: 3-CHLORO-5-FLUOROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-5-FLUOROPHENOL(202982-70-5)
• EPA Substance Registry System: 3-CHLORO-5-FLUOROPHENOL(202982-70-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: 8
• Hazardous Substances Data: 202982-70-5(Hazardous Substances Data)

Usage

Uses

3-Chloro-5-fluorophenol is used as an intermediate in organic synthesis. It plays an important role in the preparation of substituted amides as antagonists and/or inverse agonists of cannabinoid-1 receptor, substituted N-(arylmethyl)aryloxy arylcarboxamide and heteroarylcarboxamide antagonists for the PGE2 receptor EP4 for the treatment of pain, inflammation, osteoarthritis, and rheumatoid arthritis.

InChI:InChI=1/C6H4ClFO/c7-4-1-5(8)3-6(9)2-4/h1-3,9H

Upstream product

• 202925-08-4 1-chloro-3-fluoro-5-methoxybenzene 

Downstream Products

• 1311136-69-2 (5R)-3-{4-[(3-chloro-5-fluorophenyl)oxy]phenyl}-5-methyl-2,4-imidazolidinedione 
• 1311137-77-5 4-[(3-chloro-5-fluorophenyl)oxy]aniline 
• 1311137-76-4 3-chloro-5-fluorophenyl 4-nitrophenyl ether 
• 438050-33-0 3-chloro-5-fluoro-4-(hydroxymethyl)phenol 

Relevant articles and documents

HISTAMINE-3 RECEPTOR ANTAGONISTS

This invention is directed to a compound of the formula Ia or Ib. as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy- induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the Gl tract, hyper and hypo motility and acidic secretion of the gastro- intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.